CNS Pharmaceuticals (CNSP) Competitors $0.87 -0.03 (-3.60%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.90 +0.02 (+2.77%) As of 07/11/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. NAII, BCTX, LGVN, JATT, BLRX, CING, MRKR, BIVI, QTTB, and MTEXShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), JATT Acquisition (JATT), BioLineRx (BLRX), Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), Q32 Bio (QTTB), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors Natural Alternatives International Briacell Therap Longeveron JATT Acquisition BioLineRx Cingulate Marker Therapeutics BioVie Q32 Bio Mannatech Natural Alternatives International (NASDAQ:NAII) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership. Does the media refer more to NAII or CNSP? In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Natural Alternatives International. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 1 mentions for Natural Alternatives International. Natural Alternatives International's average media sentiment score of 1.91 beat CNS Pharmaceuticals' score of 0.62 indicating that Natural Alternatives International is being referred to more favorably in the media. Company Overall Sentiment Natural Alternatives International Very Positive CNS Pharmaceuticals Positive Is NAII or CNSP more profitable? CNS Pharmaceuticals has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.56%. Natural Alternatives International's return on equity of -10.34% beat CNS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.56% -10.34% -5.19% CNS Pharmaceuticals N/A -385.41%-193.20% Do analysts recommend NAII or CNSP? CNS Pharmaceuticals has a consensus price target of $25.00, suggesting a potential upside of 2,757.80%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CNS Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings & valuation, NAII or CNSP? Natural Alternatives International has higher revenue and earnings than CNS Pharmaceuticals. Natural Alternatives International is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$113.80M0.19-$7.22M-$1.39-2.51CNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00 Which has more risk and volatility, NAII or CNSP? Natural Alternatives International has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.58, suggesting that its stock price is 158% more volatile than the S&P 500. Do insiders & institutionals hold more shares of NAII or CNSP? 32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 20.9% of Natural Alternatives International shares are owned by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryNatural Alternatives International beats CNS Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.78M$2.93B$5.55B$9.08BDividend YieldN/A2.41%5.25%4.02%P/E RatioN/A20.8528.2620.26Price / SalesN/A267.57411.94152.32Price / CashN/A42.1137.1257.67Price / Book0.167.638.045.49Net Income-$14.86M-$55.05M$3.19B$250.45M7 Day Performance-5.02%8.43%3.62%4.79%1 Month Performance8.36%8.14%5.98%9.59%1 Year Performance-98.58%1.62%29.39%16.41% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.1488 of 5 stars$0.87-3.6%$25.00+2,757.8%-98.6%$4.78MN/A0.005News CoverageNAIINatural Alternatives International1.4675 of 5 stars$3.32+2.2%N/A-39.8%$20.08M$113.80M-2.39290BCTXBriacell Therap1.8978 of 5 stars$2.89-0.7%$32.00+1,007.3%-85.2%$19.72MN/A-0.358News CoverageGap DownLGVNLongeveron3.4977 of 5 stars$1.29-1.5%$8.67+571.8%-67.7%$19.56M$2.39M-0.2120News CoverageJATTJATT AcquisitionN/A$1.13+0.9%N/A-64.7%$19.49MN/A0.003High Trading VolumeBLRXBioLineRx2.6446 of 5 stars$4.32-3.8%$26.00+501.9%-83.5%$19.14M$22.34M-0.4940News CoverageAnalyst UpgradeCINGCingulate3.3248 of 5 stars$4.42+3.3%$26.00+488.2%+911.6%$18.17MN/A-0.5220News CoverageMRKRMarker Therapeutics4.5295 of 5 stars$1.57-1.9%$13.17+738.6%-67.3%$18.10M$6.59M-1.1860News CoverageBIVIBioVie1.0753 of 5 stars$8.10-15.6%N/A+53.9%$17.83MN/A-1.0210News CoveragePositive NewsQTTBQ32 Bio2.5371 of 5 stars$1.36-5.6%$12.17+794.6%-89.9%$17.57M$1.16M-0.2839Gap DownMTEXMannatech1.384 of 5 stars$8.90-3.8%N/A+19.0%$17.49M$117.87M-89.00250High Trading Volume Related Companies and Tools Related Companies NAII Competitors BCTX Competitors LGVN Competitors JATT Competitors BLRX Competitors CING Competitors MRKR Competitors BIVI Competitors QTTB Competitors MTEX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
